[Chemotherapy for gastric cancer patients over 75 years of age].
OBJECTIVE
The efficacy of chemotherapy for advanced or recurrent gastric cancer in patients who were aged over 75 years was investigated.


METHODS
Progression free survival (PFS) and overall survival (OS) of advanced gastric cancer patients who received first-line chemotherapy with TS-1 plus cisplatin or TS-1 in our hospital from 2009 to 2013 were determined. The patients were divided into two groups: H and L. H group patients were aged over 75 years, and L group patients were aged less than 75 years.


RESULTS
Median PFS and median OS of patients in the H and L groups who received TS-1 plus cisplatin chemotherapy were not significantly different. PFS was 77[range, 13-211] days and 139[range, 53-211]days for the H and L groups, respectively(p=0.141), while OS was 523[range, 22-1,030] days and 402 [range, 322-623] days, respectively (p=0.620). Similarly, median PFS and median OS of patients who received TS-1 chemotherapy were not significantly different between the H and L groups. PFS was 103[range, 51-156]days and 152.5[range, 85-278]days for the H and L groups, respectively (p=0.230), while OS was 414 [range, 224-714]days and 605[range, 452-1,077] days, respectively ( p=0.1337).


CONCLUSIONS
PFS and OS were not significantly different in younger patients with advanced gastric cancer who received TS-1 plus cisplatin or TS-1 chemotherapy compared to that in similarly treated elderly patients with advanced gastric cancer.
Dept. of Surgery, Osaka General Medical Center.
Junji
J
Kawada
Norihiro
N
Matsuura
Akihiro
A
Kitagawa
Masashige
M
Nishimura
Masatoshi
M
Nomura
Yuichiro
Y
Okumura
Susumu
S
Miyazaki
Katsuki
K
Danno
Masaru
M
Kubota
Chu
C
Matsuda
Kenichi
K
Omori
Kazuhiro
K
Nishikawa
Masaya
M
Nomura
Mari
M
Takagi
Akiko
A
Fukui
Kazumasa
K
Fujitani
Kazuhiro
K
Iwase
Yasuhiro
Y
Tanaka
D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D011379:Prognosis; D012189:Retrospective Studies; D017640:Silicates / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy*; D014025:Titanium / Q000627:therapeutic use*
D017640:Silicates; C103828:titanium silicide; D014025:Titanium; D002945:Cisplatin